Smith+Nephew Unveils Groundbreaking CPT Code for CARTIHEAL Implant
Smith+Nephew (LSE:SN, NYSE:SNN), a leading global medical technology company, is proud to announce a significant recognition from the American Medical Association (AMA) regarding its CARTIHEAL AGILI-C Cartilage Repair Implant. The AMA's CPT Editorial Panel recently established a Category I Current Procedural Terminology (CPT) code exclusively for the innovative procedures involving this implant. This new CPT code will take effect in the near future, marking a pivotal moment for both healthcare providers and patients.
The Importance of the New CPT Code
The introduction of this CPT code highlights the clinical importance and the increasing utilization of the CARTIHEAL Implant. This implant is designed as a comprehensive, off-the-shelf solution for treating cartilage and osteochondral defects in the knee, particularly beneficial for patients suffering from mild to moderate osteoarthritis (OA). Impressively, it is the only FDA-approved device specifically catering to this need, having received Breakthrough Device Designation from the U.S. Food and Drug Administration.
Clinical Evidence Supporting the CARTIHEAL Implant
Research indicates that the CARTIHEAL Implant boasts an 87% reduction in the relative risk of total knee arthroplasty or osteotomy when compared to traditional treatments such as microfracture or debridement, according to multifaceted randomized controlled trial data. This compelling evidence, along with the broad indication for osteoarthritis, positions the CARTIHEAL Implant as a vital option in treatment pathways for patients early in their clinical journey.
Expert Insights on the Innovation
Dr. Ken Zaslav from Northwell Health emphasized the significance of this new CPT code, stating, “This new CPT code is a major milestone for physicians and patients alike. It validates the clinical value of the CARTIHEAL Implant and facilitates broader access to a technology that fills a true unmet need in the world of cartilage repair.” His words reflect the optimism surrounding the adoption of this groundbreaking technology.
Enhancing Reimbursement and Access
The establishment of a Category I CPT code is poised to streamline reimbursement processes for healthcare providers and payers, which is fundamental for integrating the CARTIHEAL Implant into standard clinical practices. This recognition by the AMA underscores the clinical efficacy, safety, and growing acceptance of this innovative procedure among physicians.
Smith+Nephew's Commitment to Healthcare
Christie Van Geffen, Senior Vice President of Global Sports Medicine Marketing at Smith+Nephew, remarked, “This code represents a critical milestone on our journey to enable access to patients that can benefit from the CARTIHEAL Implant.” Such statements underscore the company’s commitment to improving patient outcomes through innovative solutions.
The CARTIHEAL AGILI-C Cartilage Repair Implant
The CARTIHEAL Implant is currently available for use across the United States, including Puerto Rico. It consists of aragonite, a naturally occurring form of calcium carbonate, and functions as a biphasic scaffold that not only aids in cartilage repair but also restores subchondral bone. This product’s design is aimed at optimizing recovery for patients suffering from knee-related issues.
Learn More About the Innovation
For further details on Smith+Nephew’s CARTIHEAL AGILI-C Cartilage Repair Implant, please visit our booth at notable medical conferences or check out our website. We are eager to share insights into how our product transforms cartilage repair methodologies.
About Smith+Nephew
Founded in Hull, UK, in 1856, Smith+Nephew has established itself as a pioneering entity in the medical technology arena, specializing in the repair, regeneration, and replacement of both soft and hard tissue. With a workforce of approximately 17,000, our mission is to enhance lives through technological advancements that facilitate healing and restore self-belief in patients. In our fiscal year, we proudly recorded $5.8 billion in annual sales, underscoring our global presence that spans around 100 countries.
Frequently Asked Questions
What is the significance of the new CPT code for the CARTIHEAL Implant?
The new CPT code signifies recognition of the clinical importance of the CARTIHEAL Implant, which should enhance its adoption in medical practices.
How does the CARTIHEAL Implant work?
It utilizes a biphasic scaffold made of aragonite, aiding in cartilage repair and restoring bone underneath the cartilage.
What are the benefits observed with the CARTIHEAL Implant?
Clinical studies show a substantial reduction in the risk of knee surgeries compared to traditional treatment options, demonstrating its effectiveness.
Who can benefit from the CARTIHEAL Implant?
Patients with knee cartilage defects, especially those experiencing mild to moderate osteoarthritis, stand to gain from this innovative treatment.
Where can I learn more about Smith+Nephew's products?
For additional information, you can visit the Smith+Nephew website or explore their presence at major medical conferences.
